StockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

Equities researchers at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report issued on Friday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

NAVB opened at $0.00 on Friday. The firm has a market capitalization of $10,008.40, a PE ratio of 0.00 and a beta of 1.15. Navidea Biopharmaceuticals has a one year low of $0.00 and a one year high of $0.13.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.